Volume 101, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Control of schistosomiasis presently relies largely on preventive chemotherapy with praziquantel through mass drug administration (MDA) programs. The Schistosomiasis Consortium for Operational Research and Evaluation has concluded five studies in four countries (Côte d’Ivoire, Kenya, Mozambique, and Tanzania) to evaluate alternative approaches to MDA. Studies involved four intervention years, with final evaluation in the fifth year. Mass drug administration given annually or twice over 4 years reduced average prevalence and intensity of schistosome infections, but not all villages that were treated in the same way responded similarly. There are multiple ways by which responsiveness to MDA, or the lack thereof, could be measured. In the analyses presented here, we defined persistent hotspots (PHS) as villages that achieved less than 35% reduction in prevalence and/or less than 50% reduction in infection intensity after 4 years of either school-based or community-wide MDA, either annually or twice in 4 years. By this definition, at least 30% of villages in each of the five studies were PHSs. We found no consistent relationship between PHSs and the type or frequency of intervention, adequacy of reported MDA coverage, and prevalence or intensity of infection at baseline. New research is warranted to identify PHSs after just one or a few rounds of MDA, and new adaptive strategies need to be advanced and validated for turning PHSs into responder villages.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. World Health Organization, 2001. Fifty-Fourth World Health Assembly Resolution WHA54.19 Schistosomiasis and Soil-Transmitted Helminth Infections. Geneva, Switzerland: World Health Organization Fifty-Fourth World Health Assembly. [Google Scholar]
  2. World Health Organization, 2012. Sixty-Fifth World Health Assembly Resolution WHA65.21 Elimination of Schistosomiasis. Geneva, Switzerland: World Health Organization Sixty-Fifth World Health Assembly. [Google Scholar]
  3. World Health Organization, 2013. Sixty-Sixth World Health Assembly Resolution WHA66.12 Neglected Tropical Diseases. Geneva, Switzerland: World Health Organization Sixty-Sixth World Health Assembly. [Google Scholar]
  4. Colley DG, Bustinduy AL, Secor WE, King CH, , 2014. Human schistosomiasis. Lancet 383: 22532264. [Google Scholar]
  5. French MD, 2018. Schistosomiasis in Africa: improving strategies for long-term and sustainable morbidity control. PLoS Negl Trop Dis 12: e0006484. [Google Scholar]
  6. McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN, , 2018. Schistosomiasis. Nat Rev Dis Primers 4: 13. [Google Scholar]
  7. World Health Organization, 2006. Preventive Chemotherapy in Human Helminthiasis: Coordinated Use of Anthelminthic Drugs in Control Interventions: A Manual for Health Professionals and Programme Managers. Geneva, Switzerland: WHO. [Google Scholar]
  8. Andrade G, Bertsch DJ, Gazzinelli A, King CH, , 2017. Decline in infection-related morbidities following drug-mediated reductions in the intensity of Schistosoma infection: a systematic review and meta-analysis. PLoS Negl Trop Dis 11: e0005372. [Google Scholar]
  9. Kabatereine NB, Brooker S, Koukounari A, Kazibwe F, Tukahebwa EM, Fleming FM, Zhang Y, Webster JP, Stothard JR, Fenwick A, , 2007. Impact of a national helminth control programme on infection and morbidity in Ugandan schoolchildren. Bull World Health Organ 85: 9199. [Google Scholar]
  10. Ezeamama AE, 2016. Gaining and sustaining schistosomiasis control: study protocol and baseline data prior to different treatment strategies in five African countries. BMC Infect Dis 16: 229. [Google Scholar]
  11. Kittur N, Binder S, Campbell CH, King CH, Kinung’hi S, Olsen A, Magnussen P, Colley DG, , 2017. Defining persistent hotspots: areas that fail to decrease meaningfully in prevalence after multiple years of mass drug administration with praziquantel for control of schistosomiasis. Am J Trop Med Hyg 97: 18101817. [Google Scholar]
  12. Wiegand RE, 2017. A persistent hotspot of Schistosoma mansoni infection in a five-year randomized trial of praziquantel preventative chemotherapy strategies. J Infect Dis 216: 14251433. [Google Scholar]
  13. Lessler J, Azman AS, McKay HS, Moore SM, , 2017. What is a hotspot anyway? Am J Trop Med Hyg 96: 12701273. [Google Scholar]
  14. Bousema T, 2010. Identification of hot spots of malaria transmission for targeted malaria control. J Infect Dis 201: 17641774. [Google Scholar]
  15. Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, Takken W, Ghani A, Drakeley C, Gosling R, , 2012. Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med 9: e1001165. [Google Scholar]
  16. World Health Organization, 2007. Guidelines on the Elimination of Residual Foci of Malaria Transmission. World Health Organization, Regional Office for the Eastern Mediterranean. [Google Scholar]
  17. Srivastava A, Nagpal BN, Joshi PL, Paliwal JC, Dash AP, , 2009. Identification of malaria hot spots for focused intervention in tribal state of India: a GIS based approach. Int J Health Geogr 8: 30. [Google Scholar]
  18. Ahmed AM, El Tash LA, Mohamed EY, Adam I, , 2012. High levels of Schistosoma mansoni infections among schoolchildren in central Sudan one year after treatment with praziquantel. J Helminthol 86: 228232. [Google Scholar]
  19. Clements AC, Bosque-Oliva E, Sacko M, Landoure A, Dembele R, Traore M, Coulibaly G, Gabrielli AF, Fenwick A, Brooker S, , 2009. A comparative study of the spatial distribution of schistosomiasis in Mali in 1984–1989 and 2004–2006. PLoS Negl Trop Dis 3: e431. [Google Scholar]
  20. Koukounari A, Gabrielli AF, Toure S, Bosque-Oliva E, Zhang Y, Sellin B, Donnelly CA, Fenwick A, Webster JP, , 2007. Schistosoma haematobium infection and morbidity before and after large-scale administration of praziquantel in Burkina Faso. J Infect Dis 196: 659669. [Google Scholar]
  21. Landoure A, 2012. Significantly reduced intensity of infection but persistent prevalence of schistosomiasis in a highly endemic region in Mali after repeated treatment. PLoS Negl Trop Dis 6: e1774. [Google Scholar]
  22. Poggensee G, Krantz I, Nordin P, Mtweve S, Ahlberg B, Mosha G, Freudenthal S, , 2005. A six-year follow-up of schoolchildren for urinary and intestinal schistosomiasis and soil-transmitted helminthiasis in northern Tanzania. Acta Trop 93: 131140. [Google Scholar]
  23. Satayathum SA, Muchiri EM, Ouma JH, Whalen CC, King CH, , 2006. Factors affecting infection or reinfection with Schistosoma haematobium in coastal Kenya: survival analysis during a nine-year, school-based treatment program. Am J Trop Med Hyg 75: 8392. [Google Scholar]
  24. Woolhouse ME, Etard JF, Dietz K, Ndhlovu PD, Chandiwana SK, , 1998. Heterogeneities in schistosome transmission dynamics and control. Parasitology 117: 475482. [Google Scholar]
  25. Assare RK, 2014. Sustaining control of schistosomiasis mansoni in moderate endemicity areas in western Cote d’Ivoire: a SCORE study protocol. BMC Public Health 14: 1290. [Google Scholar]
  26. Karanja DMS, Awino EK, Wiegand RE, Okoth E, Abudho BO, Mwinzi PNM, Montgomery SP, Secor WE, , 2017. Cluster randomized trial comparing school-based mass drug administration schedules in areas of western Kenya with moderate initial prevalence of Schistosoma mansoni infections. PLoS Negl Trop Dis 11: e0006033. [Google Scholar]
  27. Olsen A, Kinung’hi S, Magnussen P, , 2015. Schistosoma mansoni infection along the coast of Lake Victoria in Mwanza region, Tanzania. Am J Trop Med Hyg 92: 12401244. [Google Scholar]
  28. Onkanga IO, Mwinzi PN, Muchiri G, Andiego K, Omedo M, Karanja DM, Wiegand RE, Secor WE, Montgomery SP, , 2016. Impact of two rounds of praziquantel mass drug administration on Schistosoma mansoni infection prevalence and intensity: a comparison between community wide treatment and school based treatment in western Kenya. Int J Parasitol 46: 439445. [Google Scholar]
  29. Phillips AE, Gazzinelli-Guimaraes PH, Aurelio HO, Ferro J, Nala R, Clements M, King CH, Fenwick A, Fleming FM, Dhanani N, , 2017. Assessing the benefits of five years of different approaches to treatment of urogenital schistosomiasis: a SCORE project in Northern Mozambique. PLoS Negl Trop Dis 11: e0006061. [Google Scholar]
  30. Tian-Bi YT, 2018. Interrupting seasonal transmission of Schistosoma haematobium and control of soil-transmitted helminthiasis in northern and central Cote d'Ivoire: a SCORE study protocol. BMC Public Health 18: 186. [Google Scholar]
  31. WHO Expert Committee, 2002. Prevention and control of schistosomiasis and soil-transmitted helminthiasis. World Health Organ Tech Rep Ser 912: 157. [Google Scholar]
  32. Olsen A, Kinung’hi S, Magnussen P, , 2018. Comparison of the impact of different mass drug administration strategies on infection with Schistosoma mansoni in Mwanza region, Tanzania-a cluster-randomized controlled trial. Am J Trop Med Hyg 99: 15731579. [Google Scholar]
  33. World Health Organization, 2011. Helminth Control in School Age Children: a Guide for Managers of Control Programmes-2nd ed. Geneva, Switzerland: World Health Organization. [Google Scholar]

Data & Media loading...

Supplemental figure

  • Received : 08 Mar 2019
  • Accepted : 24 May 2019
  • Published online : 08 Jul 2019

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error